Health Economics›Breast cancer›Metastatic disease, all lines of therapy

Metastatic disease, all lines of therapy

Breast cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
CTCb Variant #01 Partial	—	R 6 280	—	—	~24.0 mo	—	—	1
CAF and MPA Variant #01	—	R 3 735	28d	—	—	—	—	—
STAMP-I Variant #01 Partial	—	R 2 164	—	—	—	—	—	—
Medroxyprogesterone acetate monotherapy Variant #01	—	R 1 178	28d	—	~6.0 mo	—	—	1
CAV Variant #01	—	R 760	21d	—	~7.6 mo	—	—	1
VAP Variant #01	—	R 684	21d	—	—	—	—	—
Estradiol monotherapy Variant #01	—	R 469	28d	—	—	—	—	—
TAD (Tamoxifen) N/A - secondary systemic drug	—	R 254	28d	—	—	—	—	—
Aminoglutethimide monotherapy N/A - secondary systemic drug	—	R 238	28d	—	—	—	—	—
Fluoxymesterone and Tamoxifen Variant #01 Partial	—	R 137	28d	—	—	—	—	—
Megestrol monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Formestane monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Bilateral Oophorectomy Partial	ER	—	—	—	—	—	—	—
Fluoxymesterone monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
DES monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

15 of 15 regimens shown